Zoonotic Disease Treatment Market Overview

The global zoonotic disease treatment market was valued at around USD 36.9 Billion at the end of 2021. The market is projected to register a 5.9% CAGR and top a valuation of USD 69.2 Billion by 2032.

Crowded settings, poor hygiene, fluctuating temperatures and habitats, livestock farming, and a lack of awareness are foreseen aspects supporting the growth of the zoonotic disease treatment market.

Animals often carry dangerous pathogens that can infect humans and produce zoonotic diseases, also called zoonoses. A sort of unexpected illness known as zoonosis is spread from both animals to humans and from humans to animals. Zoonotic diseases are brought on by pathogenic microorganisms such as bacteria, fungi, parasites, and viruses.

Mild to severe illnesses, even deaths can be led on by these infections in both humans and animals. Some zoonotic diseases include tuberculosis, rabies, hepatitis, and relapsing fever. Depending on the zoonotic disease, animals can occasionally seem healthy even when they are harboring pathogens that can make people sick.

Attributes Details
Zoonotic Disease Treatment Market Value in 2021 USD 36.9 Billion
Zoonotic Disease Treatment Market Value in 2032 USD 69.2 Billion
Zoonotic Disease Treatment Market CAGR (2022 to 2032) 5.9%

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

What are the Major Drivers Boosting the Demand for Zoonotic Disease Treatment Market?

Population growth, migration, and rapid urbanization are all factors that could lead to the emergence of new zoonotic diseases in the future. Due to market and production procedures for live food animals, people in urban regions are less familiar with dealing with animals than those in rural settings. The urban population may also reside in overcrowded conditions that aid in the spread of disease.

Increased demand for animal proteins is probably going to result in increased consumption of animal fats, which is going to fuel the market for zoonotic disease treatment. With millions of households owning one or more pets for companionship and entertainment. However, the possibility that some animals may carry pathogens that might infect humans when in contact is anticipated to drive the market for the same.

Which Region Shows Strong Growth Potential in the Zoonotic Disease Treatment Market?

The zoonotic disease treatment market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.

North America is the leading region in the global zoonotic disease treatment market owing to the rising population, higher rate of immigration, and rapid urbanization.

Apart from North America, the European zoonotic disease treatment market is also expected to display lucrative growth in the projected years due to the extensive livestock farming and increased consumption of animal fat in country places.

The East Asian region is predicted to show lucrative growth owing to a lack of access to safe drinking water and adequate sanitation services, which could contribute to the development of zoonotic diseases.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Who are the Key Players in the Zoonotic Disease Treatment Market?

Cadila Healthcare Ltd, AstraZeneca plc, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Johnson, Pfizer Inc., Novartis International AG, Sanofi S.A., BioCryst Pharmaceuticals, Inc, Sun Pharmaceuticals Industries, Ltd.

Scope of Report

Report Attributes Details
Growth Rate CAGR of 5.9% from 2022 to 2032
Base Year for Estimation 2021
Historical Data 2012 to 2021
Forecast Period 2022 to 2032
Qualitative Units Revenue in USD Billion, and CAGR from 2022 to 2032
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segment Covered Disease Type, Drug Class, End User, Region
Region Covered North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East Africa (MEA)
Key Countries Profiled The USA, Canada, Brazil, Mexico, Germany, The UK, France, Spain, Italy, China, Japan, South Korea, Malaysia, Singapore, Australia, New Zealand, GCC, South Africa, Israel
Key Players Cadila Healthcare Ltd; AstraZeneca plc; F. Hoffmann-La Roche AG; GlaxoSmithKline plc; Johnson Johnson; Pfizer Inc.; Novartis International AG; Sanofi S.A.; BioCryst Pharmaceuticals, Inc; Sun Pharmaceuticals Industries, Ltd.
Customization Available Upon Request

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Key Segments Covered in the Zoonotic Disease Treatment Market Report

By Disease Type:

  • Rabies
  • Hepatitis
  • Tuberculosis
  • Fever
  • Others

By Drug Class:

  • Antifungal
  • Antibacterial
  • Antibiotic
  • Others

By End User:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia Pacific
  • The Middle East and Africa (MEA)

Frequently Asked Questions

What is the Growth Outlook for the Global Zoonotic Disease Treatment Market?

The global zoonotic disease treatment market is anticipated to register a CAGR of 5.9% during the forecast period.

What is the Projected Value of the Global Zoonotic Disease Treatment Market in 2032?

The global zoonotic disease treatment market is projected to be about USD 69.2 Billion by the end of the year 2032.

Table of Content
  • 1. Executive Summary
  • 2. Industry Introduction, including Taxonomy and Market Definition
  • 3. Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
  • 4. Global Demand Analysis and Forecast, including Historical Analysis and Future Projections
  • 5. Pricing Analysis
  • 6. Global Analysis and Forecast
    • 6.1. Disease Type
    • 6.2. Drug Class
    • 6.3. End User
  • 7. Global Analysis and Forecast, By Disease Type
    • 7.1. Rabies
    • 7.2. Hepatitis
    • 7.3. Tuberculosis
    • 7.4. Fever
    • 7.5. Others
  • 8. Global Analysis and Forecast, By Drug Class
    • 8.1. Antifungal
    • 8.2. Antibacterial
    • 8.3. Antibiotic
    • 8.4. Others
  • 9. Global Analysis and Forecast, By End User
    • 9.1. Hospitals
    • 9.2. Specialty Clinics
    • 9.3. Homecare
    • 9.4. Others
  • 10. Global Analysis and Forecast, By Region
    • 10.1. North America
    • 10.2. Latin America
    • 10.3. Europe
    • 10.4. East Asia
    • 10.5. South Asia & Pacific
    • 10.6. The Middle East and Africa (MEA)
  • 11. North America Sales Analysis and Forecast, by Key Segments and Countries
  • 12. Latin America Sales Analysis and Forecast, by Key Segments and Countries
  • 13. Europe Sales Analysis and Forecast, by Key Segments and Countries
  • 14. East Asia Sales Analysis and Forecast, by Key Segments and Countries
  • 15. South Asia & Pacific Sales Analysis and Forecast, by Key Segments and Countries
  • 16. The Middle East and Africa (MEA) Sales Analysis and Forecast, by Key Segments and Countries
  • 17. Sales Forecast by Disease Type, Drug Class, and End User for 30 Countries
  • 18. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
  • 19. Company Profile
    • 19.1. Cadila Healthcare Ltd
    • 19.2. AstraZeneca plc
    • 19.3. F. Hoffmann-La Roche AG
    • 19.4. GlaxoSmithKline plc
    • 19.5. Johnson & Johnson
    • 19.6. Pfizer Inc.
    • 19.7. Novartis International AG
    • 19.8. Sanofi S.A.
    • 19.9. BioCryst Pharmaceuticals Inc
    • 19.10. Sun Pharmaceuticals Industries Ltd.

Explore Healthcare Insights

View Reports
Future Market Insights

Zoonotic Disease Treatment Market

Schedule a Call